You are here: Industry Insights > Shire

News List

Takeda Announces Issuance of Unsecured Euro Denominated Senior Notes firstwordpharma
November 09, 2018
Osaka, Japan, November 8, 2018 --- Takeda Pharmaceutical Company Limited (TSE: 4502) (the "Company or "Takeda") announces that it is planned to launch the
Takeda Comments on Ongoing Phase 1 Review by the European Commission of the Proposed Acquisition of Shire plc firstwordpharma
October 29, 2018
Takeda Comments on Ongoing Phase 1 Review by the European Commission of the Proposed Acquisition of Shire plc
Shire completes sale of oncology franchise to Servier pharmatimes
September 14, 2018
Shire has completed the sale of its oncology franchise to Servier in a deal valued at $2.4 billion.
Takeda may sell Shire assets to reduce debt following $62-billion purchase firstwordpharma
September 14, 2018
According to people close to the situation, Takeda is considering selling Shire's eye-care business, including the dry eye disease treatment Xiidra (lifitegrast)...
After FDA about-face, Amicus' Galafold nabs Fabry disease nod to challenge Sanofi fiercepharma
September 13, 2018
Amicus priced Galafold at $315,000, a slight discount from Sanofi's competitor Fabarazyme, and promised to keep future price increase below the CPI.
Shire completes sale of oncology franchise biospectrumasia
September 05, 2018
International study develops innovative method to discover new anti-epileptic drug in record time, with potential to do the same for other diseases.
Shire receives USFDA nod for TAKHZYRO biospectrumasia
August 28, 2018
TAKHZYRO is the only monoclonal antibody (mAb) that provides targeted inhibition of plasma kallikrein, an enzyme which is chronically uncontrolled in people with hereditary angioedema, to help prevent attacks
Shire eyes blockbuster sales with 'best-in-class' HAE drug Takhzyro fiercepharma
August 27, 2018
Jefferies analyst David Steinberg predicts Shire's Takhzyro could hit $1.8 billion in peak sales.
Lack of blockbuster candidates at Takeda? Don’t worry, Shire has it covered fiercepharma
August 02, 2018
Takeda’s revenue of 449.8 billion Japanese yen ($4 billion) during the April-to-June quarter was flat compared to last year. But the challenge in analysts’ eyes is not sinking Velcade sales but a lack of up-and-coming products to buoy future revenue. Luck
Shire’s fast-track NASH drug abruptly stopped in phase 2 fiercebiotech
August 01, 2018
Shire has quietly cut the trial of an FDA fast-tracked fatty liver disease drug, although it’s not giving much away about what happened.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page